Wael Al Zoughbi

Wael Al Zoughbi

Auto-generated profile, based on publicly available information

Wael Al Zoughbi

Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10021, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2024 in Engineering Applications of Artificial Intelligence
Verified
Journal Article
Open access
CKCeca Kraišniković
Ceca Kraišniković
RHRobert Harb
Robert Harb
MPMarkus Plass
Markus Plass
WZWael Al Zoughbi
Wael Al Zoughbi
Andreas HolzingerAndreas Holzinger
Andreas Holzinger
HMHeimo Müller
Heimo Müller

19 July 2021 in The Oncologist
Verified
Journal Article
Open access
PDF file
WZWael Al Zoughbi
Wael Al Zoughbi
JFJesse Fox
Jesse Fox
SBShaham Beg
Shaham Beg
EPEniko Papp
Eniko Papp
EHErika Hissong
Erika Hissong
JMJuan Miguel Mosquera
Juan Miguel Mosquera
Background Characterization of circulating tumor DNA (ctDNA) has been integrated into clinical practice. Although labs have standardized validation procedures to develop single locus tests, the efficacy of on-site plasma-based next-generation sequencing (NGS) assays still needs to be proved. Materials and Methods In this retrospective study, we profiled DNA from matched tissue and plasma samples from 75 patients with cancer. We applied an NGS test that detects clinically relevant alterations in 33 genes and microsatellite instability (MSI) to analyze plasma cell-free DNA (cfDNA). Results The concordance between alterations detected in both tissue and plasma samples was higher in patients with metastatic disease. The NGS test detected 77% of sequence alterations, amplifications, and fusions that were found in metastatic samples compared with 45% of those alterations found in the primary tumor samples (p = .00005). There was 87% agreement on MSI status between the NGS test and tumor tissue results. In three patients, MSI-high ctDNA correlated with response to immunotherapy. In addition, the NGS test revealed an FGFR2 amplification that was not detected in tumor tissue from a patient with metastatic gastric cancer, emphasizing the importance of profiling plasma samples in patients with advanced cancer. Conclusion Our validation experience of a plasma-based NGS assay advances current knowledge about translating cfDNA testing into clinical practice and supports the application of plasma assays in the management of oncology patients with metastatic disease. With an in-house method that minimizes the need for invasive procedures, on-site cfDNA testing supplements tissue biopsy to guide precision therapy and is entitled to become a routine practice. Implications for Practice This study proposes a solution for decentralized liquid biopsy testing based on validation of a next-generation sequencing (NGS) test that detects four classes of genomic alterations in blood: sequence mutations (single nucleotide substitutions or insertions and deletions), fusions, amplifications, and microsatellite instability (MSI). Although there are reference labs that perform single-site comprehensive liquid biopsy testing, the targeted assay this study validated can be established locally in any lab with capacity to offer clinical molecular pathology assays. To the authors' knowledge, this is the first report that validates evaluating an on-site plasma-based NGS test that detects the MSI status along with common sequence alterations encountered in solid tumors.

28 December 2022 in Cold Spring Harbor Molecular Case Studies
Verified
Journal Article
Open access
PDF file
JCJoanna Cyrta
Joanna Cyrta
JRJoel Rosiene
Joel Rosiene
RBRohan Bareja
Rohan Bareja
SKSarah Kudman
Sarah Kudman
WZWael Al Zoughbi
Wael Al Zoughbi
JMJuan Miguel Mosquera
Juan Miguel Mosquera
Myoepithelial carcinomas (MECs) of soft tissue are rare and aggressive tumors affecting young adults and children, but their molecular landscape has not been comprehensively explored through genome sequencing. Here, we present the whole-exome sequencing (WES), whole-genome sequencing (WGS), and RNA sequencing findings of two MECs. Patients 1 and 2 (P1, P2), both male, were diagnosed at 27 and 37 yr of age, respectively, with shoulder (P1) and inguinal (P2) soft tissue tumors. Both patients developed metastatic disease, and P2 died of disease. P1 tumor showed a rhabdoid cytomorphology and a complete loss of INI1 (SMARCB1) expression, associated with a homozygousSMARCB1deletion. The tumor from P2 showed a clear cell/small cell morphology, retained INI1 expression and strong S100 positivity. By WES and WGS, tumors from both patients displayed low tumor mutation burdens, and no targetable alterations in cancer genes were detected. P2's tumor harbored anEWSR1::KLF15rearrangement, whereas the tumor from P1 showed a novelASCC2::GGNBP2fusion. WGS evidenced a complex genomic event involving mainly Chromosomes 17 and 22 in the tumor from P1, which was consistent with chromoplexy. These findings are consistent with previous reports ofEWSR1rearrangements (50% of cases) in MECs and provide a genetic basis for the loss of SMARCB1 protein expression observed through immunohistochemistry in 10% of 40% of MEC cases. The lack of additional driver mutations in these tumors supports the hypothesis that these alterations are the key molecular events in MEC evolution. Furthermore, the presence of complex structural variant patterns, invisible to WES, highlights the novel biological insights that can be gained through the application of WGS to rare cancers.

30 April 2021 in Cancer Cytopathology
Verified
Journal Article
Closed access
PDF file
WZWael Al Zoughbi
Wael Al Zoughbi
DKDavid Kim
David Kim
SASusan Ann Alperstein
Susan Ann Alperstein
KOKentaro Ohara
Kentaro Ohara
JMJyothi Manohar
Jyothi Manohar
MSMomin T. Siddiqui
Momin T. Siddiqui

28 January 2026 in Artificial Intelligence in Medicine
Verified
Journal Article
Open access
GFGernot Fiala
Gernot Fiala
MPMarkus Plass
Markus Plass
RHRobert Harb
Robert Harb
PRPeter Regitnig
Peter Regitnig
Kristijan SkokKristijan Skok
Kristijan Skok
PHPetr Holub
Petr Holub
A Whole Slide Image (WSI) is a high-resolution digital image created by scanning an entire glass slide containing a biological specimen, such as tissue sections or cell samples, at multiple magnifications. These images are digitally viewable, analyzable, and shareable, and are widely used for Artificial Intelligence (AI) algorithm development. WSIs play an important role in pathology for disease diagnosis and oncology for cancer research, but are also applied in neurology, veterinary medicine, hematology, microbiology, dermatology, pharmacology, toxicology, immunology, and forensic science. When assembling cohorts for AI training or validation, it is essential to know the content of a WSI. However, no standard currently exists for this metadata, and such a selection has largely relied on manual inspection, which is not suitable for large collections with millions of objects. We propose a general framework to generate 2D index maps (tissue maps) that describe the morphological content of WSIs using common syntax and semantics to achieve interoperability between catalogs. The tissue maps are structured in three layers: source, tissue type, and pathological alterations. Each layer assigns WSI segments to specific classes, providing AI-ready metadata. We demonstrate the advantages of this standard by applying AI-based metadata extraction from WSIs to generate tissue maps and integrating them into a WSI archive. This integration enhances search capabilities within WSI archives, thereby facilitating the accelerated assembly of high-quality, balanced, and more targeted datasets for AI training, validation, and cancer research.

26 June 2026 in Science Advances
Verified
Journal Article
Open access
HKHui-Hsuan Kuo
Hui-Hsuan Kuo
BBBhavneet Bhinder
Bhavneet Bhinder
HGHamza N. Gokozan
Hamza N. Gokozan
KGKathryn Gorski
Kathryn Gorski
PCPooja Chandra
Pooja Chandra
MMMaria Laura Martin
Maria Laura Martin
We developed a pan-cancer patient-derived organoid (PDO) platform comprising 220 PDOs from 191 patients across 15 cancer types to advance functional precision oncology. Comprehensive characterization demonstrated high fidelity to parent tumors, with 93% histopathology concordance, 80% median genomic concordance for driver mutations, and a 0.85 median gene expression correlation. Expression profiles remained largely stable over 10 passages, ensuring reproducibility for long-term screening. Clonality analysis showed that 85% of dominant tumor clones were preserved, with genomic concordance directly reflecting clonal similarity. Even PDOs with lower concordance retained key oncogenic drivers, validating their utility as disease models. Functional assays revealed that 58% of PDOs from patients ineligible for US Food and Drug Administration–approved poly(adenosine 5′-diphosphate–ribose) polymerase inhibitors were sensitive to talazoparib, linked to DNA damage repair alterations. Furthermore, combination screens identified agents that overcome resistance, particularly in TP53 -mutant models. Our platform enables the investigation of targeted therapies and molecular drivers of drug sensitivity, providing translational insights for personalized treatment beyond current biomarker guidelines.